Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NSC668394 is a small molecule inhibitor of Radixin (RDX), a member of the Ezrin-Radixin-Moesin (ERM) protein family. ERM proteins act as cross-linkers between the plasma membrane and the actin cytoskeleton, playing crucial roles in cell shape, motility, and signal transduction. In the context of oncology, NSC668394 has been shown to suppress the migration and proliferation of astrocytoma cells and microglia by down-regulating F-actin and inhibiting RDX-mediated chemoattraction. Research indicates its potential in controlling tumor growth and invasiveness by regulating the infiltration of tumor-associated microglia in the brain tumor microenvironment, particularly in Glioblastoma Multiforme (GBM) and low-grade glioma (LGG).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NSC668394.